Form 4 for VIR Vir Biotechnology, Inc.

Accepted 2021-12-22 00:00:00 ET · period of report 2021-12-20 · accession 0001062993-21-013386 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2021-12-22	2021-12-20	VIR	NELSEN ROBERT	Dir, 10%	J - Other	$0.00	-1.75M	10.68M	-14%	$0
	2021-12-22	2021-12-20	VIR	NELSEN ROBERT	Dir, 10%	J - Other	$0.00	+102.0K	244.2K	+72%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-12-20	J	D	762,233	$0.00	8,239,380	I See footnote	—	—	(F2) The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.
2	Common	Common Stock	2021-12-20	J	A	102,041	$0.00	244,172	D	—	—
3	Common	Common Stock	2021-12-20	J	D	987,767	$0.00	10,677,283	I See footnote	—	—	(F3) The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein.